On July 29, 2026, Inhibikase Therapeutics entered into an exchange agreement with RA Capital Healthcare Fund to swap 18,030,000 shares of common stock for a pre-funded warrant. The warrant carries a $0.001 exercise price, is immediately exercisable, and has no expiration date. It includes a beneficial ownership blocker limiting holdings to 9.99% of outstanding shares, adjustable with notice up to 19.99%. This transaction was executed under Section 3(a)(9) of the Securities Act exemption. Inhibikase Therapeutics operates in the biotechnology industry, focusing on drug discovery and development.
